Shengxin Liu1, Ralf Kuja-Halkola2, Henrik Larsson2,3, Paul Lichtenstein2, Jonas F Ludvigsson2,4,5,6, Ann-Marie Svensson7,8, Soffia Gudbjörnsdottir7,8, Magnus Tideman9, Eva Serlachius10, Agnieszka Butwicka2,10,11. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. Shengxin.liu@ki.se. 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. 3. School of Medical Sciences, Örebro University, Örebro, Sweden. 4. Department of Pediatrics, Örebro University Hospital, Örebro, Sweden. 5. Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK. 6. Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. 7. Swedish National Diabetes Register, Centre of Registers, Gothenburg, Sweden. 8. Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 9. School of Health and Welfare, Halmstad University, Halmstad, Sweden. 10. Child and Adolescent Psychiatry, Stockholm Health Care Service, Region Stockholm, Sweden. 11. Department of Child Psychiatry, Medical University of Warsaw, Warsaw, Poland.
Abstract
AIMS/HYPOTHESIS: The aim of this study was to investigate the effect of childhood-onset type 1 diabetes on the risk of subsequent neurodevelopmental disorders, and the role of glycaemic control in this association. We hypothesised that individuals with poor glycaemic control may be at a higher risk of neurodevelopmental disorders compared with the general population, as well as compared with individuals with type 1 diabetes with adequate glycaemic control. METHODS: This Swedish population-based cohort study was conducted using data from health registers from 1973 to 2013. We identified 8430 patients with childhood-onset type 1 diabetes (diagnosed before age 18 years) with a median age of diabetes onset of 9.6 (IQR 5.9-12.9) and 84,300 reference individuals from the general population, matched for sex, birth year and birth county. Cox models were used to estimate the effect of HbA1c on the risk of subsequent neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorders (ASD) and intellectual disability. RESULTS: During a median follow-up period of 5.6 years, 398 (4.7%) individuals with type 1 diabetes received a diagnosis of any neurodevelopmental disorder compared with 3066 (3.6%) in the general population, corresponding to an adjusted HR (HRadjusted) of 1.31 (95% CI 1.18, 1.46) after additionally adjusting for other psychiatric morbidity prior to inclusion, parental psychiatric morbidity and parental highest education level. The risk of any neurodevelopmental disorder increased with HbA1c levels and the highest risk was observed in patients with mean HbA1c >8.6% (>70 mmol/mol) (HRadjusted 1.90 [95% CI 1.51, 2.37]) compared with reference individuals without type 1 diabetes. In addition, when compared with patients with diabetes with HbA1c <7.5% (<58 mmol/mol), patients with HbA1c >8.6% (>70 mmol/mol) had the highest risk of any neurodevelopmental disorder (HRadjusted 3.71 [95% CI 2.75, 5.02]) and of specific neurodevelopmental disorders including ADHD (HRadjusted 4.16 [95% CI 2.92, 5.94]), ASD (HRadjusted 2.84 [95% CI 1.52, 5.28]) and intellectual disability (HRadjusted 3.93 [95% CI 1.38, 11.22]). CONCLUSIONS/ INTERPRETATION: Childhood-onset type 1 diabetes is associated with an increased risk of neurodevelopmental disorders, with the highest risk seen in individuals with poor glycaemic control. Routine neurodevelopmental follow-up visits should be considered in type 1 diabetes, especially in patients with poor glycaemic control.
AIMS/HYPOTHESIS: The aim of this study was to investigate the effect of childhood-onset type 1 diabetes on the risk of subsequent neurodevelopmental disorders, and the role of glycaemic control in this association. We hypothesised that individuals with poor glycaemic control may be at a higher risk of neurodevelopmental disorders compared with the general population, as well as compared with individuals with type 1 diabetes with adequate glycaemic control. METHODS: This Swedish population-based cohort study was conducted using data from health registers from 1973 to 2013. We identified 8430 patients with childhood-onset type 1 diabetes (diagnosed before age 18 years) with a median age of diabetes onset of 9.6 (IQR 5.9-12.9) and 84,300 reference individuals from the general population, matched for sex, birth year and birth county. Cox models were used to estimate the effect of HbA1c on the risk of subsequent neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorders (ASD) and intellectual disability. RESULTS: During a median follow-up period of 5.6 years, 398 (4.7%) individuals with type 1 diabetes received a diagnosis of any neurodevelopmental disorder compared with 3066 (3.6%) in the general population, corresponding to an adjusted HR (HRadjusted) of 1.31 (95% CI 1.18, 1.46) after additionally adjusting for other psychiatric morbidity prior to inclusion, parental psychiatric morbidity and parental highest education level. The risk of any neurodevelopmental disorder increased with HbA1c levels and the highest risk was observed in patients with mean HbA1c >8.6% (>70 mmol/mol) (HRadjusted 1.90 [95% CI 1.51, 2.37]) compared with reference individuals without type 1 diabetes. In addition, when compared with patients with diabetes with HbA1c <7.5% (<58 mmol/mol), patients with HbA1c >8.6% (>70 mmol/mol) had the highest risk of any neurodevelopmental disorder (HRadjusted 3.71 [95% CI 2.75, 5.02]) and of specific neurodevelopmental disorders including ADHD (HRadjusted 4.16 [95% CI 2.92, 5.94]), ASD (HRadjusted 2.84 [95% CI 1.52, 5.28]) and intellectual disability (HRadjusted 3.93 [95% CI 1.38, 11.22]). CONCLUSIONS/ INTERPRETATION: Childhood-onset type 1 diabetes is associated with an increased risk of neurodevelopmental disorders, with the highest risk seen in individuals with poor glycaemic control. Routine neurodevelopmental follow-up visits should be considered in type 1 diabetes, especially in patients with poor glycaemic control.
Authors: Dimitrios Charalampopoulos; Julia M Hermann; Jannet Svensson; Torild Skrivarhaug; David M Maahs; Karin Akesson; Justin T Warner; Reinhard W Holl; Niels H Birkebæk; Ann K Drivvoll; Kellee M Miller; Ann-Marie Svensson; Terence Stephenson; Sabine E Hofer; Siri Fredheim; Siv J Kummernes; Nicole Foster; Lena Hanberger; Rakesh Amin; Birgit Rami-Merhar; Anders Johansen; Knut Dahl-Jørgensen; Mark Clements; Ragnar Hanas Journal: Diabetes Care Date: 2018-04-12 Impact factor: 19.112
Authors: Agnieszka Butwicka; Paul Lichtenstein; Mikael Landén; Anna S Nordenvall; Anna Nordenström; Agneta Nordenskjöld; Louise Frisén Journal: J Child Psychol Psychiatry Date: 2014-07-22 Impact factor: 8.982
Authors: Agnieszka Butwicka; Louise Frisén; Catarina Almqvist; Björn Zethelius; Paul Lichtenstein Journal: Diabetes Care Date: 2015-02-03 Impact factor: 19.112
Authors: Elena Sokolova; Anoek M Oerlemans; Nanda N Rommelse; Perry Groot; Catharina A Hartman; Jeffrey C Glennon; Tom Claassen; Tom Heskes; Jan K Buitelaar Journal: J Autism Dev Disord Date: 2017-06
Authors: Setareh Alabaf; Christopher Gillberg; Sebastian Lundström; Paul Lichtenstein; Nóra Kerekes; Maria Råstam; Henrik Anckarsäter Journal: J Autism Dev Disord Date: 2019-01